Supplementary
: Relationship between treatment arm and overall survival by proportion of tumour (study cohort divided into 5 equally sized groups (quintiles). A. biopsy proportion of tumour ≤41.86%: no significant difference in overall survival between treatment arms, HR (95% confidence interval): 1.31 (0.74, 2.33), p=0.3602. B. biopsy proportion of tumour between 41.86% and 51.39%: no significant difference in overall survival between treatment arms, HR (95% confidence interval): 1.29 (0.73, 2.27), p=0.3803. C. biopsy proportion of tumour between 51.39% and 59.73%: patients treated with neoadjuvant combination therapy followed by surgery survive significantly longer than those treated by surgery alone, HR (95% confidence interval): 2.64 (1.44, 4.84), p=0.0011. D. biopsy proportion of tumour between 59.73% and 69.38%: patients treated with neoadjuvant combination therapy followed by surgery survive significantly longer than those treated by surgery alone, HR (95% confidence interval):1.87 (1.00, 3.49), p=0.0457. E. biopsy proportion of tumour >69.38%: no significant difference in overall survival between treatment arms, HR (95% confidence interval): 0.73 (0.41, 1.27), p=0.2573. (76) 36 (78) 139 (76) 38 (73) Female 68 (24) 10 (22) 44 (24) 14 (27) Tumour site Upper third 3 (1) 1 (2) 2 (1) 0 (0) Middle third 66 (23) 8 (17) 42 (23) 16 (31) Lower third 191 (68) 36 (78) 122 (67) 33 (63) Cardia 21 (7) 1 (2) 17 (9) 3 (6) Histology Adeno 195 (69) 38 (83) 129 (70) 28 (54) Squamous 84 (30) 7 (15) 53 (29) 24 (46) Other 2 (1) 1 (2) 1 (1) 0 (0) 
